期刊文献+

HER-2基因特异性核酶设计与体外转录载体构建

Construction of Design of HER-2 Specific Ribozyme Genes and Its Transcription Vector in Vitro
下载PDF
导出
摘要 目的构建人表皮生长因子受体-2(HER-2)特异性核酶(ribozyme,RZ)及其底物基因的体外转录载体.方法设计合成RZ基因,将该RZ克隆到真核表达载体pcDNA3.1(+)中,测序鉴定.应用Trizol试剂提取MDA-MB-453细胞总RNA,RT-PCR扩增靶基因HER-2 cDNA片段,同样插入载体pcDNA3.1(+),测序鉴定.结果经DNA测序分别证实合成的RZ基因序列和通过RT-PCR扩增的HER-2 cDNA序列克隆入pcDNA3.1(+)中.结论构建HER-2特异性RZ真核表达载体及含有HER-2 cDNA的载体,有助于进一步研究RZ对靶基因切割作用及雌激素受体阴性乳腺癌细胞MDA-MB-453中HER-2信号转导通路. Objective To construct the transcription vectors of genes of HER-2 specific ribozyme and its substrate in vitro. Methods According to design of computer,the ribozyme gene was synthesized,then was cloned into the eukaryotic expression vector peDNA3.1 (+). The positive recombinants were analyzed by DNA sequencing. Trizol reagent facilitated isolation of total RNA from MDA-MB-453 cells. The HER-2 eDNA gene sequence amplified by reverse transcription polymerase chain reaction( RT-PCR) was inserted into the same vector peDNA3.1( + ).The HER-2 positive recombinants were analyzed by DNA sequencing. Results The reeombinants containing the ribozyme gene and the HER-2eDNA gene proved by DNA sequencing were cloned into pcDNA3.1( + ). Conclusion A hammerhead ribozyme,the eukaryotic expression vector with the RZ and in vitro transcription vector with HER-2 gene were constructed. It helps to study deeply cleavage of ribozyme targeting HER-2 mRNA and the HER-2 signal transduetion pathway of estrogen receptor negative breast cancer cells MDA-MB-453.
出处 《北华大学学报(自然科学版)》 CAS 2008年第5期417-419,共3页 Journal of Beihua University(Natural Science)
基金 吉林省教育厅科研基金项目(2006-87)
关键词 人表皮生长因子受体-2(HER-2) 锤头状核酶 基因治疗 HER-2 Hammerhead ribozyme Gene therapy
  • 相关文献

参考文献8

二级参考文献22

  • 1陈艺华.癌基因、抗癌基因异常与人乳腺癌[J].中华病理学杂志,1994,23(2):122-124. 被引量:12
  • 2Feng M,Cancer Res,1995年,55卷,10期,2024页
  • 3彭朝晖,基因治疗.基础与临床,1994年,163页
  • 4Dahiya R, Deng G. Molecular prognostic markers in breast cancer. Breast Cancer Res &Treat,1998;52(1-3):185.
  • 5Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survivalwith amplification of the HER-2/neu oncogene.Science,1987;235(4785):177.
  • 6Kallioniemi OP. Association of C-erbB2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor longterm survival in breast cancer. Int J Cancer,1991;49(5):650.
  • 7Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of C-erbB2 expression in breast cancer. J Surg Oncol,2002;79(4):216.
  • 8Ring AE, Ellis PA. Predictors of response to systemic therapy in breast cancer. Forum,2002;12(1):19.
  • 9Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech,2002;59(2):102.
  • 10Revillion F, Bonneteree J, Peyrat JP. ErbB-2 oncogene in human breast cancer and its clinical significance. Eur J Cancer,1998;34(6):791.

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部